Tylenol Arthritis Sales Provide J&J Some Buffer From Currency Headwinds
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson’s US consumer segment sales grow 7.7% to $3.31bn, fueled by 29% growth of analgesics products. Currency headwinds continue to hammer the firm’s overall performance, while management seeks to ensure investors the business is healthy despite effects.